Liver-directed regional therapy in the multi-disciplinary management of hepatocellular cancer

Current Cancer Therapy Reviews

Volumn 6, Issue 1, 2010, Pages 19-25

  Senthil, Maheswari ^a   Mailey, Brian ^a   Leong, Lucille ^a   Chung, Vincent ^a   Yen, Yun ^a   Chen, Yi Jen ^a   Marx, Howard ^a   Kim, Joseph ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Chemoembolization; Hepatocellular cancer; Liver directed therapy; Radioembolization; Regional therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MICROSPHERE; TAMOXIFEN; YTTRIUM 90;

ABDOMINAL PAIN; BILIARY TRACT DISEASE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG HALF LIFE; DRUG PENETRATION; FEVER; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER TOXICITY; MALAISE; MORBIDITY; NAUSEA; PATIENT SELECTION; POSTEMBOLIZATION SYNDROME; PRIORITY JOURNAL; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; VOMITING;

EID: 77949891779     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410790596461     Document Type: Review

References (56)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-23.
4. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107.
5. Hong SN, Lee SY, Choi MS, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005; 39: 247-52.
6. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
7. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007; 25: 978-86.
8. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl 1): S20-37.
9. Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C. Hepatic, arterial embolization in patients with malignant liver tumours (author's transl). Ann Radiol (Paris) 1974; 17: 593-603.
10. Minakuchi K, Nakatsuka H, Nakamura K, Sato M, Tamaoka K, Yamada R. Transcatheter vascular embolization in the management of hemorrhage. Nippon Igaku Hoshasen Gakkai Zasshi 1979; 39: 924-34.
11. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
12. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
13. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
14. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology 1988; 94: 453-6.
15. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
16. Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 2001; 32: 383-9.
17. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
18. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129-34.
19. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
20. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
21. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-32.
22. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
23. Veltri A, Morretto P, Doriguzzi A, et al. Radiofrequency thermal ablation after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16: 661-9.
24. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
25. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
26. Stuart K. Chemoembolization in the management of liver tumors. Oncologist 2003; 8: 425-37.
27. Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009; 72: 505-16.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
29. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248: 617-25.
30. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81.
31. Sacco R, Bertini M, Bertoni M, et al. Clinical impact of selective trans-arterial chemoembolization on hepatocellular carcinoma: a cohort study. World J gastroenterol 2009; 15: 1843-48.
32. Caturelli E, Siena DA, Saverio F, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: Evaluation of damage to non-tumorous liver tissue-Long-term prospective study. Radiology 2000; 215: 123-8.
33. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-75.
34. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 200-8.
35. Lewin K, Millis RR. Human radiation hepatitis: a morphologic study with emphasis on the late changes. Arch Pathol 1973; 96: 21-6.
36. Minsky BD, Leibel SA. The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. Cancer Treat Rev 1989; 16: 213-9.
37. Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70: 2250-4.
38. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17: 1251-78.
39. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16: 205-13.
40. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: S194-205.
41. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-39.
42. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41: 1673-81.
43. 90Yttrium microspheres. Int J Radiat Oncol Phys 1998; 40: 583-92.
44. Sangro B, Bilbao J, Boan J, et al. Radioembolization using 90Y-resin micropsheres for patients with advanced hepatocellular carcinoma. Int J Radiol Oncol Phys 2006; 66: 792-9.
45. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 1375-82.
46. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33: 919-24.
47. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008;19: 691-7.
48. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16: 660-5.
49. Fan J, Wu ZQ, Tang ZY, et al. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 2001; 7: 28-32.
50. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15: 335-45.
51. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
52. Kim DY, Kwon DS, Salem R, Ma CK, Abouljoud MS. Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. J Gastrointest Surg 2006; 10: 413-6.
53. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma : chemoembolization versus radioembolization. Am J Transplantation 2009; 9: 1-9.
54. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
55. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
56. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.